Latest Breaking News On - Edesa biotech - Page 3 : comparemela.com

Insider Buying: Edesa Biotech, Inc (NASDAQ:EDSA) CEO Acquires $20,000 00 in Stock

Edesa Biotech, Inc. (NASDAQ:EDSA – Get Free Report) CEO Pardeep Nijhawan acquired 5,000 shares of the stock in a transaction dated Monday, March 25th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $20,000.00. Following the purchase, the chief executive officer now directly owns 341,702 shares in […]

Pardeep nijhawanCm managementDimensional fund advisorsCibc world market incSecurities exchange commissionEdesa biotech incMillennium managementRenaissance technologiesEdesa biotechGet free reportExchange commissionFund advisorsWorld marketEdesa biotech dailyNasdaq edsaInsider trading

Pardeep Nijhawan Acquires 5,000 Shares of Edesa Biotech, Inc (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA – Get Free Report) CEO Pardeep Nijhawan purchased 5,000 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $4.00 per share, for a total transaction of $20,000.00. Following the completion of the transaction, the chief executive officer now directly […]

Pardeep nijhawanCibc world market incRenaissance technologiesDimensional fund advisorsCm managementEdesa biotech incMillennium managementSecurities exchange commissionEdesa biotechGet free reportExchange commissionFund advisorsCibc world marketEdesa biotech dailyNasdaq edsaInsider trading

Edesa Biotech, Inc (NASDAQ:EDSA) CEO Pardeep Nijhawan Purchases 5,000 Shares

Edesa Biotech, Inc (NASDAQ:EDSA) CEO Pardeep Nijhawan Purchases 5,000 Shares
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Pardeep nijhawanDimensional fund advisorsEdesa biotech incCibc world market incRenaissance technologiesMillennium managementCm managementEdesa biotechGet free reportFund advisorsCibc world marketEdesa biotech daily

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its bu.

United statesUnited kingdomStephen lemieuxGary koppenjanAmerican contact dermatitis society annual meeting onExchange commissionEdesa biotech incSecurities exchangeBritish columbia securities commissionAmerican academy of dermatology annual meetingStrategic innovation fundEdesa biotechAcute respiratory distress syndromePar nijhawanChief executive officerChief financial officer stephen lemieux

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

United statesStephen lemieuxNews networkSecurities exchangeAmerican contact dermatitis society annual meeting onAmerican academy of dermatology annual meetingStrategic innovation fundEdesa biotech incEdesa biotechAcute respiratory distress syndromePar nijhawanChief executive officerChief financial officer stephen lemieuxAllergic contact dermatitisThree months ended decemberStrategic innovation